Condition: Multimorbidity · Healthy · Sponsor: Ove Andersen
The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models. We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.
This description comes directly from the study's public registry record.
Juliette Tavenier · +4538620640 · juliette.tavenier@regionh.dk
Line Jee Hartmann Rasmussen · +4538620640 · line.jee.hartmann.rasmussen@regionh.dk
Always discuss trial participation with your own doctor first.
| Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre | Hvidovre, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06431932